Exelixis
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: Alameda, California, United States, North America
Region: California
Country: US
Continent: North America
About
Exelixis is an oncology-focused biotech company developing cancer therapies, with a broad multi-platform approach that includes biotherapeutics and small-molecule programs. The company emphasizes discovery, development, and commercialization of cancer medicines aimed at treating multiple tumor types and improving patient outcomes. It highlights in-house discovery capabilities such as bispecific antibodies and antibody-drug conjugates, as well as strategic collaborations to advance its pipeline. Headquartered and operating in the United States, Exelixis communicates its mission of bringing innovative oncology treatments to patients and advancing science in cancer care.
Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes cancer therapies. The firm utilizes a multi-platform approach, including small molecules and biotherapeutics, to treat various tumor types. Its primary customers are healthcare providers and patients requiring oncology treatments.
Exelixis Inc.
1994
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
432300000
200m-1b
ipo
NASDAQ:EXEL
nasdaq
Investors
Founders
Corey Goodman
Stelios Papadopoulos
Leadership
Gisela S. Schwab — Executive VP and Chief Medical Officer
Stelios Papadopoulos — Founder
Michael Morrissey — President and CEO
Pragalath Sundararajan — Scientist III, Discovery Biology
Christopher Senner — Executive Vice President and Chief Financial Officer
Dana Aftab — Executive Vice President, Research and Development
Technology Stack
Products
CABOMETYX (cabozantinib): A small molecule tyrosine kinase inhibitor used to treat various advanced cancers by targeting multiple receptor pathways involved in tumor growth and angiogenesis.
Zanzalintinib: An investigational next-generation tyrosine kinase inhibitor targeting MET, VEGFR, AXL, and MER, being evaluated for treatment of multiple solid tumors including colorectal and kidney cancers.
XL309: A USP1 inhibitor in early clinical development aimed at treating solid tumors by targeting ubiquitin-specific peptidase 1 to disrupt tumor cell survival mechanisms.
XB010: A next-generation antibody-drug conjugate targeting 5T4 antigen, designed to deliver cytotoxic agents directly to tumor cells in solid tumors.
XB628: A bispecific antibody targeting PD-L1 and NKG2A receptors, designed to modulate immune response against solid tumors.
ADU-1805: A monoclonal antibody targeting SIRPα, under clinical investigation to enhance immune-mediated tumor cell clearance in solid tumors.
Funding rounds
POST_IPO_EQUITY · 135000000 · (2015-07-01T00:00:00)
IPO · 118000000 · (2000-04-01T00:00:00)
EARLY_VC · 8870000 · (1999-02-01T00:00:00)
SERIES_A · 7680000 · (1996-03-01T00:00:00)
SEED · 3130000 · (1995-03-01T00:00:00)